摘要
目的探讨布地奈德、特布他林、沐舒坦雾化吸入治疗慢性阻塞性肺疾病急性加重期(AECO-PD)的临床疗效。方法符合AECOPD诊断标准的103例患者,随机分为治疗组51例和对照组52例,两组均采用综合治疗,治疗组加用布地奈德、特布他林、沐舒坦联合雾化吸入,对照组加用布地奈德单一雾化吸入,治疗后对两组的症状、体征改善时间进行比较。结果治疗组在喘憋缓解时间、哮鸣音消失时间及咳嗽缓解时间方面与对照组比较差异有统计学意义(P<0.01)。结论在常规治疗的基础上应用布地奈德、特布他林、沭舒坦联合雾化吸入治疗AECOPD疗效显著,且方便、简单、安全。
Objective To investigate the clinical effects of aerosol inhalation treatment of budesonide, terbutal-ine and ambroxol on moderate to severe AECOPD. Methods 103 patients with moderate to severe AECOPD were randomly divided into treatment group（ n = 51 ） and control group （n = 52 ）. Both groups were treated with comprehen-sive therapy. Treatment group was treated with budesonide, terbutaline, ambroxol inhalation and control group was trea- ted with budesonnide inhalation, then the relief time of symptoms and signs were compared after treatment. Results The time of asthmatic relief, disappearance of wheeze and cough relief of the treatment group were superior to those of the control group,there was significant difference between the two groups （ P 〈 0. 01 ）. Conclusion On the basis of routine treatment, application of budesonide, terbutaline and ambroxol has significant effects on patients with AECOPD and it is convenient, simple and safe.
出处
《实用药物与临床》
CAS
2013年第6期536-538,共3页
Practical Pharmacy and Clinical Remedies
